Mark Hillen

Content by Mark Hillen:

Business & Profession Retina

Generally Regarded as Safe

02/25/2018 | Mark Hillen

A saccharine story of the more you learn, the less you know.

888

02/21/2018 | Mark Hillen

Subspecialties Cataract

Making the Subjective Objective

02/01/2018 | Mark Hillen

So much of premium IOL selection comes down to chair time and questionnaires. But what if it didn’t?

Subspecialties Retina

Reducing Revitrectomy Risk

01/31/2018 | Mark Hillen

Study suggests that systemic statins lower the risk of revitrectomy in RRD.

Subspecialties Retina

Drops of Silence!

01/09/2018 | Mark Hillen

Arresting AMD: topical siRNA therapy could be the future

Subspecialties Retina

Peerless

01/09/2018 | Mark Hillen

Can any other specialty match ophthalmology when it comes to pushing medicine forwards?

Subspecialties Retina

Quite a Stretch

12/07/2017 | Mark Hillen

Can brolucizumab extend the AMD anti-VEGF treatment interval?

Business & Profession Other

Heidelberg Man

12/07/2017 | Mark Hillen

Another lament to the loss of a leading figure in ophthalmology…

Subspecialties Retina

Does Size Really Matter?

11/02/2017 | Mark Hillen

A (much) closer look at vitrectomy instrument size.

Subspecialties Cataract

Polymers and PCO: the IOL Material Lowdown

11/02/2017 | Mark Hillen

When you have a big dataset, what was once suspected can now be confirmed.

1
2
3
4
5
...

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

Unlimited access to ALL articles
News, interviews & opinions from leading industry experts
Receive print (and PDF) copies of The Ophthalmologist magazine

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: